Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
Stephanie Sembill(Universitätsklinikum Erlangen), Markus Metzler(Friedrich-Alexander-Universität Erlangen-Nürnberg), Krzysztof Kałwak(Poznan University of Medical Sciences), Fiorina Giona(Sapienza University of Rome), Nora Naumann‐Bartsch(Friedrich-Alexander-Universität Erlangen-Nürnberg), Meinolf Suttorp(Technische Universität Dresden), Manuela Krumbholz(Universitätsklinikum Erlangen), Alexander Kiani(Bayreuth Medical Center), Maria Ampatzidou(Children's Hospital Agia Sophia), Hiroyuki Shimada(Keio University), Birgitta Versluijs(Utrecht University), Maaike Luesink(Princess Máxima Center), Kirk R. Schultz(University of British Columbia), Michael Dworzak(St. Anna Children's Cancer Research Institute), C. Michel Zwaan(Princess Máxima Center), Barbara De Moerloose(Ghent University Hospital), Sonali Chaudhury(Northwestern University), Nobuko Hijiya(Lurie Children's Hospital), Frédéric Millot(Université de Poitiers), Michael Osborn, Petr Sedláček(University Hospital in Motol), Axel Karow
Cited by 30
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577